OBESITY

TYPE 2 DIABETES

NASH

Type 2 Diabetes is the fastest growing chronic disease in the world today.  It is estimated that more than 380 million people worldwide suffer from it, 27 million in the US alone and the number is projected to increase to over 592 million by 2035.

Diabetes is also associated with a wide range of serious medical conditions.  Diabetes is the leading cause of cause of blindness, kidney failure and limb amputations in adults. 

According to the American Diabetes Association, the annual cost of treating T2DM in the US alone is $245 billion, which represents 1 in 10 healthcare dollars.  This translates to an average of $9,500 in direct costs, per patient per year.

Worldwide, the number of obese people has increased dramatically, nearly doubling in just the past 30 years.  Recent studies have shown that more than 200 million men and nearly 300 million women are obese.

Obesity is the fifth leading risk for global deaths.  In addition, a significant percentage of those who are obese deal with an increased burden from diabetes, heart disease, and certain cancers.

Each year, more than $140 billion is spent in the US on healthcare costs associated with obesity.  Obese adults spend 42 percent more on direct healthcare costs than adults who are a healthy weight.

Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a buildup of fat in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease (NAFLD).

NASH can get worse and cause scarring of the liver, which leads to cirrhosis, a chronic condition that can lead to total liver failure requiring liver transplantation.

NASH affects nearly 40 million people in the US and and currently has no effective pharmocological treatment. The disease is estimated to cost the US healthcare system over $30 billion dollars annually.

Metamodix is focused on developing drug-free, nonsurgical device therapies to address metabolic diseases such as Type 2 diabetes, Obesity and NASH.